For innovation companies, highly differentiated and technologically advanced biobetters offer the greatest potential to mitigate the risks associated with the introduction of biosimilars, as they can be approved before the patent expires and have blockbuster potential.
Related Articles Read More >

Proscia achieves ISO 27001 security certification

New Dotmatics Luma scientific data platform helps enable AI and ML in life sciences

DoMore Diagnostics and Proscia partner to inform personalized treatment decisions for colorectal cancer patients
